enGene Holdings Inc. (NASDAQ: ENGN) reported its first‑quarter 2026 financial results, showing a net loss of $29.8 million for the three months ended January 31, 2026, compared with a $24.6 million loss in the same period a year earlier. The company’s operating expenses increased to $31.2 million, up from $26.6 million in Q1 2025, driven by higher research and development and general‑administrative costs as the company prepares for a pivotal LEGEND trial cohort and a planned Biologics License Application filing later in the year.
The company posted earnings per share of –$0.44, beating analyst estimates of –$0.55 (and –$0.60 from Raymond James). The EPS beat was driven by disciplined cost management and the absence of one‑time charges, allowing the company to narrow its loss despite higher operating expenses.
Cash, cash equivalents and marketable securities stood at $312.5 million as of January 31, 2026, giving the company a runway that extends into the second half of 2028. enGene also expanded its loan and security agreement with Hercules Capital, Inc. to a total of $125 million, of which $25 million was drawn at the time of the amendment. The additional non‑dilutive capital supports development and potential commercialization of its lead product, detalimogene voraplasmid, for high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer.
The company highlighted that the expanded debt facility and strong liquidity position it to meet the costs of the upcoming LEGEND pivotal cohort update, the anticipated 12‑month complete response data due in the second half of 2026, and the planned BLA submission. These developments underscore enGene’s focus on advancing its non‑viral gene therapy platform while maintaining financial flexibility as it approaches a critical regulatory milestone.
Management emphasized the progress: "As data from LEGEND's pivotal cohort in high‑risk, BCG‑unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference," said President and CEO Ron Cooper. He added, "On the heels of our successful November follow‑on offering, we entered 2026 in a position of financial strength and ready to execute. With RMAT and CDRP designations for detalimogene, we are in active dialogue with the FDA to ensure regulatory and manufacturing readiness as we plan for a BLA submission in the second half of this year and potential launch in 2027."
Investors reacted cautiously, focusing on the widening net loss despite the company’s robust cash position and expanded debt facility. The market’s attention was drawn to the company’s strong liquidity and regulatory progress, balanced against the higher operating costs associated with late‑stage development and public‑company operations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.